S M Assad

MD(General Medicine)@GMCNagpur|DM(Nephrology) @OffCMCVellore|ESENeph|@GlomCon Fellow 2025|SoMe Team @CMCNephrology @ISNSCOON2026

[Roger Rodby @NephRodby]

Join us, @Rush_Nephrology for a LIVE on ZOOM renal biopsy conference tomorrow Thursday 6/4 at 1 PM CST. Sit down before you read this next statement: we are presenting a transplant case, albeit with a twist. #RushRenalRules

[Nephrology Journal Club @NephJC]

#TenPostNephJC
#NephTwitter #NephJC
1/10
How often do we miss non-diabetic kidney disease (NDKD)?
🚩NDKD are 1) active urine sediment, 2) sudden worsening RFT, 3) absence of retinopathy 4) systemic symptoms like rash
@Tiff_Caza
https://t.co/0H9Rydx60J

[Nephrology Journal Club @NephJC]

Check out the VA from @dra_miliflores
On kidney biopsies in patients with diabetes #NephJC #NephTwitter
https://t.co/D6VMQN0ko8

[Akshaya Jayachandran 🇮🇳 @DrAkshayaJ]

1/7 ☕️🩺
“Can my CKD patients still drink coffee?”

The evidence is getting more interesting than expected
This review in @NDTsocial ➡️ Moderate coffee intake is probably safe in CKD, may even be beneficial.
@ERAkidney
https://t.co/cnFjKPbjyU
I'm a☕️addict, couldn't help tweet.

[Int Society of Nephrology @ISNkidneycare]

The IgAN Nephropathy curriculum provides a comprehensive review of the pathogenesis, treatment, and prediction of disease progression to help clinicians in their work.

Access the curriculum, supported by Otsuka: https://t.co/fizctiscAq #IgAN

[S M Assad @assad_sm]

When we biopsy a patient with diabetes, are we simply confirming diabetic nephropathy, or searching for a potentially treatable non-diabetic kidney disease?

Do check out this latest #NephJC blog exploring the clinical and histologic predictors of NDKD.
#NephTwitter

[Nephrology Journal Club @NephJC]

Do you biopsy pts with diabetes? Are you looking for diabetic nephropathy or something else?
Check out the blog by @dra_miliflores and @drpriyajohn
📣Now with a "audio abstract" at the top. Listen in the car to see if you want to read more! #NephTwitter
https://t.co/hNhGv45a54

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Diabetic Nephropathy (DN) with concurrent primary podocytopathy represents a distinct clinical entity characterized by nephrotic-range proteinuria, ultrastructural podocyte effacement and favorable response to immunosuppressive therapy ca. 2026 from @NDTsocial
#Nephpearls #ECNeph

Early renal biopsy incorporating Foot Process Width (FPW) assessment enables targeted therapy to mitigate ESKD progression in this high-risk phenotype.

https://t.co/tdJLMh1zMd

[S M Assad @assad_sm]

@CristinaDeReins Thank you @CristinaDeReins . Grateful and excited for this. #NephJC

[S M Assad @assad_sm]

@DrAkshayaJ Thank you @DrAkshayaJ for the mentorship and support. Looking up to some exciting days ahead and lots of shared learning and collaboration ! ✨

[Nephrology Journal Club @NephJC]

✨Exciting news #Nephtwitter

The new #NephJC editorial interns are here!

📢 Give them a follow and make them feel at home https://t.co/iqe5dTLD4A

@DrBarbaTeba @AncaSt13 @dany_rcal @kiddo_kidney @AndrewDelaat @farahwehbe92 @rn_flex @assad_sm
@ManoleaA @Nihal_Hamary

[Akshaya Jayachandran 🇮🇳 @DrAkshayaJ]

🚨This interesting webinar by @isn_india & @ISGDtweets is 🗓️today !!

Advances in Podocytopathy covering MCD, FSGS & MN, with interactive cases.

@kdjhaveri @drshyambansal @koyaljainMD @jradnephro @raja_1980 @SwatiAr76730089✨

[Akshaya Jayachandran 🇮🇳 @DrAkshayaJ]

Join us for the next #ECNeph by @ISNeducation

📚 Nephrotic syndrome in a diabetic – playbook 101 with a twist
🗓️ May 28
⏰ 8:00 PM IST

Diabetic + nephrotic proteinuria - is it just DKD ?👀

@edgarvlermamd @myadla @Dilushiwijay @DrGeetikaSingh1 @dakidneydoc @ISNkidneycare

[KIReports @KIReports]

Randomized Controlled Trial of #Dapagliflozin for Post-Transplant Diabetes Mellitus #PTDM in Renal #Transplant Recipients

#VisualAbstract by @DrAkshayaJ

https://t.co/A7OxxFjgfM

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

SAVE THE DATE for upcoming #ECNeph
"Nephrotic syndrome in a patient with diabetes"
🗓️ 28th May, Thursday
⏰ 8PM IST 🇮🇳, 1030AM EST 🇺🇸, 1030PM PHT 🇵🇭
#Nephpearls

[Wisit Cheungpasitporn MD FACP | FASN | FAST @wisit661]

😊🙏🏻Excited to share our new publication in American Journal of Kidney Diseases:
@AJKDonline

“Deceased Donor Kidney Transplantation Versus Continued Dialysis Among Patients Aged 75 Years or Older: A Target Trial Emulation.”

https://t.co/ZzSVe1eO6T

This study addresses a clinically important and increasingly common question in nephrology and transplant medicine:
Should carefully selected adults ≥75 years old remain on dialysis or pursue deceased donor kidney transplantation?

Using a target trial emulation framework with sequential trials methodology, we analyzed outcomes among transplant-eligible older adults listed in the OPTN registry from 2015–2023.

Key findings:

* Kidney transplantation in adults ≥75 years was associated with an early postoperative mortality risk during the first 90 days.
* Survival benefit emerged gradually over time, with a break-even point around 3 years.
* By 5 years, deceased donor kidney transplantation conferred an approximately 111-day survival advantage compared with remaining on dialysis.
* Findings support individualized decision-making rather than a one-size-fits-all approach for older transplant candidates.

Importantly, the study highlights that dialysis may remain a reasonable alternative for some older adults, particularly when considering frailty, symptom burden, quality of life, and competing risks.

Congratulations to all co-authors and collaborators on this important work in advancing evidence-based care for older adults with kidney failure.

Authors: Napat Leeaphorn, Rose Mary Attieh, Katherine M. Oshel, Oscar A. Garcia Valencia, Wisit Cheungpasitporn, Tambi Jarmi, and colleagues.

@napatlee1 @OscarGarciaMD @MayoClinicNeph

📍
National Kidney Foundation @nkf

#Nephrology #KidneyTransplant #Transplantation #Dialysis #KidneyDisease #AJKD #TargetTrialEmulation #ClinicalResearch #ESKD #KidneyCare

[Roger Rodby @NephRodby]

Please join us TODAY for a LIVE @Rush_Nephrology renal biopsy conference today THURSDAY 5/21/26 at 1:00 PM CST. Today's theme "You may look well but you are not". #RushRenalRules

[Nephrology Journal Club @NephJC]

Hypertension control remains stubbornly low in underserved communities. IMPACTS‑BP asks whether a team‑based, multi‑component approach can meaningfully improve blood pressure control and adherence in low‑income patients

🎨#VisualAbstract by @DrAkshayaJ

https://t.co/liZjXaThwl

[KIReports @KIReports]

1/ Hey #NephTwitter! 👋
We’re back with a fresh #Xtorial
@ISNkidneycare
This review article in @KIReports looks at the MASLD - CKD axis- It's epidemiology, mechanisms,screening & therapy.
Key idea: It's not just coexistence, but shared biology.
https://t.co/2jNPHSeXlp
@DrAkshayaJ

[S M Assad @assad_sm]

12/ Take-home:
✔️ Confirm true resistance
✔️ Exclude white-coat effect
✔️ Assess adherence
✔️ Optimize diuretics
✔️ Add spironolactone
✔️ Treat lifestyle + secondary causes
Most resistant HTN can be improved with a structured approach.

[S M Assad @assad_sm]

This World Hypertension Awareness Day, let’s discuss a topic which is quite relevant to us as nephrologists.

🧵 Resistant Hypertension: the 2026 update
A quick practical review based on the recent JAMA paper by Azizi et al. 👇

doi:10.1001/jama.2026.1221

@isn_india @ISHBP

[S M Assad @assad_sm]

11/ Resistant HTN is not benign.
True resistant HTN is associated with:
💔 Higher cardiovascular mortality
☠️ Higher all-cause mortality
Needs systematic evaluation, not just “more tablets.”